Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bolt Biotherapeutics, Inc. (BOLT : NSDQ)

• Company Description    Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company's pipeline reflects biology and cancer drug development. Its lead program includes BDC-4182. Bolt Biotherapeutics Inc., formerly known as BOLT THERAPT, is based in REDWOOD CITY, Calif. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $4.14 Daily Weekly Monthly 20 Day Moving Average: 22,159 shares Shares Outstanding: 1.93 (millions) Market Capitalization: $7.98 (millions) Beta: 1.00 52 Week High: $7.20 52 Week Low: $3.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.43% 12.68% 12 Week 7.53% 1.42% Year To Date -24.29% -33.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 900 CHESAPEAKE DRIVE - REDWOOD CITY,CA 94063 USA ph: 650-665-9295 fax: - sarah.mccabe@sternir.com http://www.boltbio.com

• General Corporate Information    Officers William P. Quinn - President; Chief Executive Officer and Chief Finan Brian O'Callaghan - Chairman Sarah Nemec - Senior Vice President; Finance Laura Berner - Director Kathleen LaPorte - Director Peer Information Bolt Biotherapeutics, Inc. (CORR.) Bolt Biotherapeutics, Inc. (RSPI) Bolt Biotherapeutics, Inc. (CGXP) Bolt Biotherapeutics, Inc. (BGEN) Bolt Biotherapeutics, Inc. (GTBP) Bolt Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 097702203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 1.93 Most Recent Split Date: 6.00 (0.05:1) Beta: 1.00 Market Capitalization: $7.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.01 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.10 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.63 Price/Cash Flow: - Price / Sales: 1.70 EPS Growth vs. Year Ago Period: -2.47% vs. Previous Quarter: -6.03% Sales Growth vs. Year Ago Period: -99.72% vs. Previous Quarter: -80.77% ROE 09/30/26 - - 06/30/26 - -126.23 03/31/26 - -100.89 ROA 09/30/26 - - 06/30/26 - -54.70 03/31/26 - -48.23 Current Ratio 09/30/26 - - 06/30/26 - 2.61 03/31/26 - 3.51 Quick Ratio 09/30/26 - - 06/30/26 - 2.61 03/31/26 - 3.51 Operating Margin 09/30/26 - - 06/30/26 - -611.47 03/31/26 - -455.15 Net Margin 09/30/26 - - 06/30/26 - -611.47 03/31/26 - -455.15 Pre-Tax Margin 09/30/26 - - 06/30/26 - -611.47 03/31/26 - -455.15 Book Value 09/30/26 - - 06/30/26 - 6.58 03/31/26 - 10.32 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 1.47 03/31/26 - 0.98 Debt-to-Capital 09/30/26 - - 06/30/26 - 59.45 03/31/26 - 49.40

Powered by Zacks Investment Research ©